Aurinia Pharmaceuticals Inc.

AUPH · Healthcare · $2.0B mkt cap · FY2025 filings · Shallow moat ·

Doesn't clear the bar

Shallow moat
Share / Embed this score
Embed this score

The five investor questions

85

2021–2025 (latest 5 aligned FYs; v3 window cap 5): revenue $45.6M to $283M, increasing; diluted EPS -1.40 to 2.07, increasing.

97

Median gross margin 95.8% over 7y, very stable.

5

Median ROIC -28.3%, above the 12% hurdle in 14% of years.

73

Net debt/EBITDA n/ax, interest coverage 24x.

24

Owner earnings changed trend unclear over up to the ten most recent annual observations.

Price vs. value if growth stopped today

A cautious baseline, not a price target: what the shares may support if normalized owner earnings simply hold steady.

Above value if growth stopped todayBelow value if growth stopped today
No price data
Not reported
Unavailable — insufficient owner-earnings data
Unavailable — insufficient growth-model data
$15.35
No price data

This zero-growth estimate assumes trailing owner earnings persist — unreliable for declining businesses. Flag status unavailable — four adjacent recent FY revenue observations are required.

Model details under moat-index@3.0.0: zero-growth multiple 11.1×, capped-growth comparison at no more than 18×; 9% discount rate; high-end growth 0% (capped at 4%) using min(5y revenue CAGR, 5y diluted-EPS CAGR), clamped to 0%–4%; maintenance capex uses min(capex, D&A); abstain when D&A is unavailable. This is a disclosed model range, not intrinsic value as fact.

Fundamentals

We couldn't reach the fundamentals service just now, so we won't show a stale or guessed series for AUPH. Try again shortly.

Visual explainers

The filing-backed explainer service is temporarily unavailable, so no partial or guessed chart is shown.

Moat Score history

16 logged readings since Jul 17, 2026 · append-only, never rewritten

Moat Score over timeLast scored reading of each day, on the 0–100 scale56.8 / 100
0406080100WideNarrowShallowNo moatJul 17, 2026Jul 26, 2026

Breaks in the line mark methodology or normalizer upgrades — readings across versions aren’t compared, so a level shift there isn’t a change in the business.

Tier changesSame-methodology and same-normalizer crossings of the Wide / Narrow / Shallow bars

  1. Normalizer upgraded unstamped (version unknown)tomoat-xbrl-normalizer@1.1.0 — readings across versions aren’t comparedJul 26, 2026
  2. Methodology upgraded moat-index@2.0.0tomoat-index@3.0.0 — readings across versions aren’t comparedJul 23, 2026
  3. Methodology upgraded moat-index@1.2.0tomoat-index@2.0.0 — readings across versions aren’t comparedJul 20, 2026

Scores are logged append-only and never overwritten — this record cannot be reconstructed retroactively, which is exactly why it’s worth keeping.

Insider activity

Form 4 reports mix P/S market or private transactions with compensation-plan mechanics. Activity casually described as “insider selling” can include compensation mechanics; awards, tax withholding, and option exercises are shown by their exact filed class here, never collapsed into “Bought” or “Sold.”

These are disclosed filing facts and arithmetic aggregates, not a signal or verdict.

The insider-filing service is temporarily unavailable, so no partial or guessed answer is shown for AUPH.

Healthcare context

#130 of 728 scored Healthcare companies, ranked by Moat Score.

Nearest peers by Moat Score

  1. #128TALK TALKSPACE, INC.56.9 out of 100, Shallow moatShallow moat
  2. #129TECH BIO-TECHNE Corp56.8 out of 100, Shallow moatShallow moat
  3. #131PODD INSULET CORPORATION56.6 out of 100, Shallow moatShallow moat
  4. #132MIND MIND TECHNOLOGY, INC56.3 out of 100, Shallow moatShallow moat

Compare AUPH with its nearest peersAll Healthcare companies on the Index →

Common questions about AUPH

Does Aurinia Pharmaceuticals Inc. have an economic moat?
Based on its FY2025 SEC filings, the Moat Index scores Aurinia Pharmaceuticals Inc. (AUPH) 56.8 out of 100 — a Shallow moat. The five questions behind that score begin at 20% each; if exactly one genuinely lacks data, the other four weights are renormalized and disclosed. revenue and EPS trend 85, pricing power 97, returns on capital 5, balance-sheet safety 73, capital allocation 24.
How has AUPH's Moat Score changed over time?
The record logs 16 readings since Jul 17, 2026; the latest reads 56.8 out of 100 (shallow moat). No tier changes on record yet. (Methodology or normalizer upgrades on Jul 20, 2026, Jul 23, 2026, Jul 26, 2026 re-based the score; readings across versions aren't compared.) The history is append-only — readings are only ever added, never rewritten.